OTCM
FAMDF
Market cap987kUSD
Oct 08, Last price
0.00
1Q
33.33%
Jan 2017
-99.58%
IPO
-99.79%
Name
Futura Medical PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
Key people
Interim Chief Executive Officer · since 2025
Angela Hildreth
Finance Director, Chief Operating Officer, Company Secretary, Executive Director · since 2018
Ken James
Executive Director, Head of R&D · since 2016
Jeffrey Robert Needham
Independent Non-Executive Chairman of the Board · since 2023
Independent Non-Executive Director · since 2024
Independent Non-Executive Director · since 2024
Andrew Unitt
Senior Non-Executive Independent Director · since 2022
Headquarters & legal address
Surrey Technology Centre
40 Occam Road
Guildford, SRY GU2 7YG
GB
40 Occam Road
Guildford, SRY GU2 7YG
GB
Previous name
FUTURA (HOLDINGS) PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||